Unaudited Financials Results for the 3rd Quarter ended on 31st December, 2025

Profit growth above 25%Adverse audit opinionEmphasis of matterResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹0.37

prior close

₹0.36

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%-1.2% vs market

Pharmaceuticals peers, median of 156sector-0.9%-1.8% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7-1.5-1.2-0.9-1.8

Next day

-5.4-2.2-3.2-1.4-4.0

-8.1-1.2-6.9-0.9-7.2

-10.8-0.9-9.9-0.5-10.3

-10.8-2.3-8.5-2.0-8.8

-5.4-2.5-2.9-2.2-3.2

-8.1-3.6-4.5-2.8-5.4

15d

-21.6-10.4-11.2-6.9-14.8

-27.0-11.3-15.7-8.6-18.4

-8.1-3.6-4.5-3.4-4.7

-21.6+3.9-25.5+0.9-22.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Welcure Drugs & Pharmaceuticals reported its Q3 FY26 standalone results showing Revenue from Operations of Rs 0 (nil) for the quarter, down sharply from Rs 6,562.40 lakhs in Q2 FY26 and Rs 883.80 lakhs in Q3 FY25. The company earned Rs 146.43 lakhs in 'Other Income' in Q3, resulting in a Profit After Tax of Rs 106.67 lakhs (EPS Rs 0.13). For the nine months ended December 2025, total revenue surged to Rs 36,700.26 lakhs vs Rs 2,455 lakhs in the prior year period, driven by a complete business shift into the Agriculture segment (Rs 36,553.83 lakhs) while the legacy Drugs & Pharmaceuticals segment reported zero revenue. Nine-month PAT jumped to Rs 4,340.27 lakhs from Rs 95.56 lakhs. The statutory auditor issued a Disclaimer of Opinion, citing inability to obtain sufficient audit evidence and noting that external confirmations for debtors, creditors, investments and loans were not obtained.

Likely market impact

Short-term shareholders may be alarmed by the zero Q3 revenue from operations, the auditor's disclaimer of opinion, and the unexplained strategic exit from the pharma segment. However, the 9-month picture shows strong topline and bottomline growth now coming entirely from agriculture — investors should seek clarity on sustainability, segment economics, and reasons for the auditor's reservations.